

# **GLC: Implementation of the new Global Framework for Management of Multidrug-Resistant Tuberculosis**

**Dr Aamir Khan**

21<sup>st</sup> Stop TB Partnership Coordinating Board meeting, 31  
January 2012  
Bangkok, Thailand

# Contents

- The Global Framework
- Progress in implementation of each element
- Implications and issues
- Next steps

# The Global Framework for Management of MDR-TB

## **Goal: Universal Access to DR-TB Management by 2015**

1. Increased level of technical support to countries
2. Increased access to high-quality, affordable SLDs
3. Strengthened advocacy
4. Regular monitoring and evaluation of country performance
5. Regular updating of international policy and guidelines
6. Provision of advice to funding agencies upon their request

# New Global Framework - installation

- Endorsed by the STP CB (Apr 2011) and WHO STAG (June 2011)
- New framework in place as of 1 July 2011
- Global GLC (gGLC) established, met in October 2011, will meet again this month
- gGLC secretariat established in WHO Geneva

## New Global Framework - installation

- Regional GLC (rGLCs) established in American, European and the Western Pacific regions,
- With rGLC secretariats in each Regional Office
- Strong push for rapid establishment of rGLCs in remaining regions (gGLC, Core Group of MDR-TB Working Group, Partnership, WHO), and in WHO Regional Offices
- African, Eastern Mediterranean, South East Asian rGLCs on track for implementation Q2, 2012.

## **New Global Framework – role of the MDR-TB Core Group**

- Advocacy for MDR-TB scale-up
- Support implementation of key strategic recommendations from sub-groups
- Governance and reporting to Coordinating Board
- Coordination with other Workings Groups

# Increased level of technical support to countries

- 47 monitoring and TA missions to 39 countries with GF grants, Q 3 & 4, 2011, compared to 46 in same period 2010
- 97 reviews of SLD procurements by g and rGLC Secretariats, Q 3 & 4, 2011, compared to 70 in same period 2010
- Missions to improve eM&E, Nepal and Uzbekistan through key partners (IRD, MSH); Myanmar and Cameroon missions planned
- Guidelines on electronic recording and reporting for TB care and control developed by WHO with KNCV and MSH through TB-CARE
- Training workshops on M&E for MDR-TB in 3 regions (AMR, EMR, EUR)
- Justification for 2 year indicative budget, exercise was stopped

## Increased access to high-quality, affordable SLDs

- Direct access to GDF for procurement of quality assured SLDs
- SLD Market Stakeholders group established, involving many partners, with long term goal of all MDR-TB patients having access to quality assured SLDs at a cost that most countries can afford or one that donors prepared to pay



## Strengthened advocacy

- EURO MDR-TB Action Plan

## Regular monitoring and evaluation of country performance

- rGLCs establishing routine annual M&E of countries
- WHO Annual MDR-TB Progress Report
- Progress report on MDR-TB to the WHA, 2012
- Performance benchmarks to assess progress of new framework - 2<sup>nd</sup> gGLC meeting in Feb 2012

## **Regular updating of international policy and guidelines**

- WHO 2011 Updated PMDT Guidelines
- Handbook on community based MDR-TB care, by TBCARE (Oct 2011)
- MDR-TB Planning Tool by PATH, with WHO

## **Provision of advice to funding agencies upon their request**

- Technical advice provided on request to TGF on 8 countries

## **Funding for framework (via WHO)**

### **USAID PEPFAR grant for Financial Year Oct 2011- Sept 2012 to support GF grants**

- Recently approved - USD \$2.4m

### **MoU between TGF and WHO**

- New MoU for provision of technical support via the gGLC and rGLCs, hopefully will be finalised soon.
- However funding less than for 2011.

### **Eli Lilly MDR-TB Partnership, 3<sup>rd</sup> Phase**


- Under discussion. Funds may be available Q4 2012; main focus on China, India, the Russian Federation and South Africa

# “Totally Drug Resistant” TB

- Report of 4 cases from Mumbai, India
- Intense media interest
- Response
  - In India: From Government of India, State of Maharashtra and Mumbai Municipal Authority, civil society
  - WHO: Messages to media, FAQs, technical consultation in March 2012, joint CDC-WHO letter
- Implications for GDF
  - Supply of Class 5 drugs: challenges linezolid and clofazimine
- Opportunity offered for advocacy on strengthened TB control activities (all aspects) and resource mobilization, needs to be seized

## Doubling of notified MDR-TB cases in 2009-10. However only 16% of total global estimated cases enrolled on treatment in 2010

Notified MDR-TB cases (2007–2010) and projected numbers of patients to be enrolled on treatment (2011–2012) compared with targets in the GPSTB 2011–2015



# Concluding Summary


- Framework of GLC is established and working
- Focus now on MDR-TB scale up in countries
- Advocacy for MDR-TB is the urgent priority
- Realignment of the MDR Working Group's role to support advocacy and scale-up in progress

Donor	Total Income (including any balance carried forward)	Expenditure Breakdown (includes encumbrances) as of 30 September 2011					Total expenditure	Balance
		GLC activities, trainings, meetings and partner contracts	WHO-HQ GLC salaries	GLC regional services		Programme support costs		
				WHO-RO/CO Salaries	Technical assistance to countries			
USAID	2,062,815 <sup>b</sup>	0	448,160	0	1,294,788	226,583	1,969,531	93,284
Global Fund	3,670,133	357,740	985,473	1,104,271	150,000	181,824	2,779,308	890,825
UNITAID /TBP	174,000	0	130,500	0	0	0	130,500	43,500
ELI LILLY	116,000	0	0	0	71,262	9,264	80,526	35,474
WHO- Regular Budget	33,000	0	24,750	0	0	0	24,750	8,250
<b>TOTAL</b>	<b>6,055,948</b>	<b>357,740</b>	<b>1,588,883</b>	<b>1,104,271</b>	<b>1,516,050</b>	<b>417,671</b>	<b>4,984,615</b>	<b>1,071,333</b>

<sup>a</sup>As of 30 September 2011

<sup>b</sup>This amount includes the portion of grant allocated to GLC for M&E, technical assistance to countries and salaries and does not include LAB, IC and DRS components

Outcomes of MDR-TB treatment for MDR-TB patients started on treatment in 2008\*



\* In countries reporting outcomes for >200 MDR-TB cases with <20% unevaluated (cohort size shown below country names)



# CSE payments by quarter, 2010-2011

